MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales milestone payments with a potential value of up to$592 million, as well as royalties on salesMSD retains an option for a second vaccine candidate, EVX-B2, for which the evaluation period is extended with a decision on potential lic ...